IBEX 35
11.154,60 +170,90 (+1,56%) Euro Stoxx 50
5.006,85 +67,84 (+1,37%) Dólar/Euro
1,0699 -0,0034 (-0,32%) Petróleo Brent
89,36 +0,35 (+0,39%) Oro
2.349,60 +7,10 (+0,30%) Bitcoin EUR
59.712,39 +880,13 (+1,50%)
Inventiva S.A. (0RNK.L)
Inventiva S.A.
50 rue de Dijon
Daix 21121
France
33 3 80 44 75 00
https://www.inventivapharma.com
Sector(es):
Sector:
Empleados a tiempo completo: 120
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer, Deputy CEO & Director | 413,46k | N/A | 1962 |
| Mr. Frederic Cren | Co-Founder, CEO & Chairman | 504,46k | N/A | 1966 |
| Mr. Jean Volatier | Deputy GM & CFO | N/A | N/A | 1965 |
| Ms. Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer | N/A | N/A | 1971 |
| Mr. Eric Duranson L.L.M. | General Counsel | N/A | N/A | 1974 |
| Ms. Nathalie Harroy | Head of Human Resources | N/A | N/A | 1967 |
| Dr. Michael Cooreman | Chief Medical Officer | N/A | N/A | 1958 |
| Ms. Pascaline Clerc Ph.D. | Executive Vice President of Strategy & Corporate Affairs | N/A | N/A | 1980 |
Descripción
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Gobierno corporativo
El ISS Governance QualityScore de Inventiva S.A., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 8; Derechos de los accionistas: 9; Compensación: 5.
